Plasma amyloid-beta ratios in autosomal dominant Alzheimer’s disease: the influence of genotype

Antoinette O’Connor, MRCP1,2*, Josef Panné, PhD3,4*, Teresa Poole, MSc1,5*, Charles Arber, PhD6, Erik Portelius, PhD3,4, Imogen Swift, MSc2, Amanda J Heslegrave, PhD2, Emily Abel, MSc2, Nanet Willumsen, PhD6, Helen Rice, MSc1,2, Philip SJ Weston, PhD1, Natalie S Ryan, PhD1,2, James M Polke PhD7, Jennifer M Nicholas PhD1,5, Simon Mead PhD6,9, Selina Wray PhD6, Lucia Chávez-Gutiérrez PhD10,11, Chris Frost MA DipStat (Cantab)5, Kaj Blennow, MD, PhD3,4, Henrik Zetterberg, MD, PhD2,3,4 # and Nick C Fox, FMedSci1,2#

*/# contributed equally

(1) Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom

(2) UK Dementia Research Institute at UCL, London, United Kingdom

(3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

(4) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

(5) Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, United Kingdom

(6) Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK

(7) Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK

(8) National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK

(9) MRC Prion Unit at UCL, UCL Institute of Prion Diseases, 33 Cleveland Street, London W1W 7FF, UK

(10) VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium

(11) Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium

Corresponding author: Professor Nick C Fox, email: n.fox@ucl.ac.uk, telephone: +44 (0)20 3448 477, address: First floor, 8-11 Queen Square, London, WC1N 3AR

Manuscript word count: 2720/2500
Abstract: 199/200 words: No abbreviations

*In-vitro* studies of autosomal dominant Alzheimer’s disease implicate longer amyloid-beta peptides in pathogenesis, however less is known about the behaviour of these mutations *in-vivo*. In this cross-sectional cohort study, we used liquid chromatography-tandem mass spectrometry to analyse 66 plasma samples from individuals who were at-risk of inheriting a pathogenic mutation or were symptomatic. We tested for differences in plasma amyloid-beta42:38, 42:40 and 38:40 ratios between *presenilin1* and *amyloid precursor protein* carriers. We examined the relationship between plasma and *in-vitro* models of amyloid-beta processing and tested for associations with parental age at onset. 39 participants were mutation carriers (28 *presenilin1* and 11 *amyloid precursor protein*). Age- and sex-adjusted models showed marked differences in plasma amyloid-beta between genotypes: higher amyloid-beta42:38 in *presenilin1* versus *amyloid precursor protein* (p<0.001) and non-carriers (p<0.001); higher amyloid-beta38:40 in *amyloid precursor protein* versus *presenilin1* (p<0.001) and non-carriers (p<0.001); while amyloid-beta42:40 was higher in both mutation groups compared to non-carriers (both p<0.001). Amyloid-beta profiles were reasonably consistent in plasma and cell lines. Within *presenilin1*, models demonstrated associations between amyloid-beta42:38, 42:40 and 38:40 ratios and parental AAO. *In-vivo* differences in amyloid-beta processing between *presenilin1* and *amyloid precursor protein* and carriers provide insights into disease pathophysiology, which can inform therapy development.
INTRODUCTION

Understanding Alzheimer’s disease (AD) pathogenesis is critical to realising disease-modifying treatments. Autosomal dominant Alzheimer’s disease (ADAD), caused by mutations in presenilin 1/2 \((PSEN1/2)\) or amyloid precursor protein \((APP)\), is a valuable model for characterising the molecular drivers of AD (Ryan et al., 2016).

\(\text{PSEN1}\), the catalytic subunit of \(\gamma\)-secretase, sequentially cuts \(\text{APP}\): initial endopeptidase cleavage generates an amyloid-beta \((\text{A}\beta)\) peptide, either \(\text{A}\beta49\) (major product) or \(\text{A}\beta48\) (minor product) (Sato et al., 2003). Subsequent proteolysis largely occurs down two pathways: \(\text{A}\beta49>46>43>40\) or \(\text{A}\beta48>45>42>38\) (Takami et al., 2009). As \(\text{A}\beta49\) is the predominant endopeptidase cleavage product, normal \(\text{APP}\) processing largely leads to \(\text{A}\beta40\) formation (Sato et al., 2003). Pathogenic ADAD mutations alter \(\text{APP}\) processing resulting in more, and/or longer, aggregation prone, \(\text{A}\beta\) peptides, which accelerate cerebral amyloid accumulation leading to typical symptom onset in 30s to 50s (Bateman et al., 2012; Chávez-Gutiérrez et al., 2012).

Both \(\text{APP}\) and \(PSEN1/2\) mutations increase production of longer (e.g. \(\text{A}\beta42\)) relative to shorter (e.g. \(\text{A}\beta40\)) peptides (Chávez-Gutiérrez et al., 2012). However, there are intriguing inter-mutation differences in \(\text{A}\beta\) profiles. \(\text{PSEN1}\) mutant lines produce increased \(\text{A}\beta42:38\) ratios reflecting impaired \(\gamma\)-secretase processivity (Chávez-Gutiérrez et al., 2012; Arber et al., 2019). In contrast, \(\text{APP}\) mutations at the \(\gamma\)-secretase cleavage site increase \(\text{A}\beta38:40\) ratios, consistent with preferential processing down the \(\text{A}\beta48\) pathway (Arber et al., 2019). To date, studies examining the influence of ADAD genotypes on \(\text{A}\beta\) ratios \(\text{in-vivo}\) have been lacking.
Increasingly sensitive mass spectrometry-based assays now make it possible to measure concentrations of different Aβ moieties in plasma (Schindler et al., 2019a). Therefore, we aimed to analyse plasma Aβ levels in an ADAD cohort, explore influences of genotype and clinical stage, and examine relationships between ratios and both age at onset (AAO) and estimated years to/from symptom onset (EYO), while also assessing consistency with in-vitro models of Aβ processing.

METHODS

Study design and participants

We recruited 66 participants from UCL’s longitudinal ADAD study; details described previously (Ryan et al., 2016). Samples were collected from August 2012 to July 2019 and concomitantly a semi-structured health questionnaire and clinical dementia rating (CDR) scale were completed (Morris, 1993). EYO was calculated by subtracting parental AAO from the participant’s age. Participants were defined as symptomatic if global CDR was >0. ADAD mutation status, determined using Sanger sequencing, was provided only to statisticians, ensuring blinding of participants and clinicians. The study had local Research Ethics Committee approval; written informed consent was obtained from all participants or a consultee.

Measurement of plasma Aβ levels

EDTA plasma samples were processed, aliquotted, and frozen at −80°C according to standardised procedures and shipped frozen to the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, for analysis blinded to participants’ mutation status and diagnosis. Samples were analysed using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method using an optimized protocol for immunoprecipitation for improved analytical sensitivity (Appendix 1, Supplementary Fig. 1) (Pannee et al., 2014). Pooled plasma
samples were used to track assay performance; intra- and inter-assay coefficients of variation were <5%.

**Correlation of Aβ ratios in plasma and in induced pluripotent stem cell (iPSC) neurons**

A sub-study investigated the consistency of Aβ profiles between plasma and iPSC-derived neurons. Aβ profiles were compared based on mutation for 8 iPSC-lines; data from 6 iPSC-lines previously reported (Arber *et al.*, 2019). Mutations tested were APP V717I (n=2), PSEN1 Intron 4 (n=1), Y115H (n=1), M139V (n=1), R278I (n=1) and E280G (n=2). Plasma and iPSC samples were from the same participant or, where matched plasma was unavailable, plasma from a carrier of the same mutation, and if possible a family member. Aβ42:40, Aβ38:40 and Aβ42:38 ratios were normalised by taking the ratio of the median ratio in controls for each experimental setting (n=27 non-carriers for plasma, n=5 iPSC controls lines from non-ADAD families) (ratio values Supplementary Table 1).

iPSC-neuronal Aβ was quantified as previously reported (Arber *et al.*, 2019). Briefly, iPSCs were differentiated to cortical neurons for 100 days and then 48 hour-conditioned culture supernatant was centrifuged removing cell debris. Aβ was analysed via electrochemiluminescence on the MSD V-Plex Aβ peptide panel (6E10), according to manufacturer’s instructions.

**Statistical analysis**

Summary descriptive statistics were calculated by mutation type (*PSEN1, APP, non-carriers*) and box plots produced for Aβ42:38, Aβ38:40 and Aβ42:40 ratios. Box plots were presented by mutation type (*PSEN1 vs APP vs non-carriers*), and then individually for *PSEN1* and *APP* carriers by clinical stage (presymptomatic vs symptomatic vs non-carriers) (Fig. 1). Aβ ratios
are displayed on logarithmic scales. Age- and sex-adjusted differences were estimated between mutation type for each ratio; as were differences by clinical stage for each ratio, separately for APP and PSEN1 carriers. These comparisons were made using mixed models including random intercepts for clusters comprising individuals from the same family and group, with random intercept and residual variances allowed to differ for the groups being compared. Pairwise comparisons were only carried out if a joint test provided evidence of differences. Ratios were log-transformed; estimated coefficients were back-transformed to multiplicative effects.

The relationship between parental AAO, EYO and age (EYO=age–AAO) meant it was not straightforward to separate out effects of AAO and EYO on Aβ ratios and adjust for age. This is because the relationship between EYO and AAO implies that once one adjusts for age, the effects of AAO and EYO are aliased i.e. if age is held constant then a one-year increase in AAO implies a one year decrease in EYO and vice versa. Therefore, to investigate the relationship between each (log) ratio and parental AAO, a mixed model was run that adjusted for sex and EYO while also taking an age effect into account. To achieve this, the model estimated the effect of ‘normal ageing’ in non-carriers and then allowed for this (by subtracting this ageing component) when estimating the effect of AAO (adjusted for sex and EYO) in mutation carriers. These analyses were run separately for PSEN1 and APP participants. For Aβ42:38 in PSEN1 carriers there was evidence also to include a quadratic term for parental AAO. The models allowed for the same random effects for family and group as in the group comparisons. In each analysis the estimated geometric mean ratio (and 95% confidence interval) was plotted against parental AAO, standardising to an equal mix of males/females, an EYO of 0 (i.e. the point of symptom onset), and adjusted for ‘normal ageing’ relative to age 43 (the average age of mutation carriers).
Separately, for \textit{PSEN1} and \textit{APP} carriers, the same type of model investigated the relationships between each ratio and EYO, adjusting for sex, AAO and ‘normal ageing’. Here the plots of estimated geometric mean ratio (and 95% confidence interval) against EYO were standardised to an equal mix of males/females, an AAO of 43 (average age of mutation carriers), and adjusted for ‘normal ageing’ relative to age 43. Spearman correlation coefficients were calculated to assess the association between plasma and iPSC-neuron Aβ ratios.

Analyses were performed using Stata v16.

\textbf{Data availability}

Data are available upon reasonable request from qualified investigators, adhering to ethical guidelines.

\textbf{RESULTS}

Demographic and clinical characteristics are presented in Table 1: 27 non-carriers; 39 mutation carriers (28 \textit{PSEN1}, 11 \textit{APP}); Supplementary Table 2 gives mutation details.

Age- and sex-adjusted models showed marked differences in plasma Aβ between \textit{PSEN1} and \textit{APP} carriers. The geometric mean of Aβ42:38 was higher in \textit{PSEN1} compared to both \textit{APP} carriers (69\% higher, 95\%CI 39\%, 106\%; p<0.001) and non-carriers (64\% higher, 95\%CI 36\%, 98\%; p<0.001), while there was no evidence of a difference between \textit{APP} carriers and non-carriers (p= 0.60) (Fig. 1A).

Plasma Aβ42:40 was raised in both \textit{PSEN1} and \textit{APP}; compared to non-carriers the adjusted geometric mean was 31\% higher (95\%CI 16\%, 49\%; p<0.001) in \textit{PSEN1} and 61\% higher
(95% CI 44%, 80%; p<0.001) in APP (Fig. 1D). There were also inter-mutation differences in Aβ42:40: the geometric mean was 22% higher (95% CI 8%, 38%; p=0.001) in APP compared to PSEN1 carriers.

The geometric mean of Aβ38:40 was higher in APP carriers compared to both PSEN1 carriers (101% higher, 95% CI 72%, 135%; p<0.001) and non-carriers (61% higher, 95% CI 41%, 84%; p<0.001) (Fig. 1G). While in PSEN1, Aβ38:40 was reduced compared to non-carriers (geometric mean 20% lower, 95% CI 10%, 29%, p<0.001).

For Aβ42:40 ratios, group differences remained significant when separately comparing non-carriers to (i) presymptomatic (18% higher, 95% CI 3%, 36%, p=0.02) and symptomatic (47% higher, 95% CI 23%, 76%, p<0.001) PSEN1 carriers, and to (ii) presymptomatic (62% higher, 95% CI 44%, 82%, p<0.001) and symptomatic (62% higher, 95% CI 37%, 92%, p<0.001) APP carriers (Figs. 1E, 1F). Within PSEN1, the geometric mean of Aβ42:40 was also 24% higher (95% CI 2%, 52%; p=0.03) in symptomatic compared to presymptomatic carriers (Fig. 1E). There were no statistically significant differences between presymptomatic and symptomatic PSEN1 carriers in Aβ42:38 (p=0.11; Fig 1B) or Aβ38:40 (p=0.54; Fig. 1H). Additionally, no significant differences were observed in the Aβ42:40, Aβ42:38 or Aβ38:40 ratios between presymptomatic and symptomatic APP carriers (all p values>0.50) (Fig. 1C, 1F, 1I).

Using models that adjusted for sex, EYO and ‘normal ageing’, we found significant associations between all three ratios and parental AAO in PSEN1 carriers (all p-values <0.03) (Fig. 2). Higher Aβ42:38 and Aβ42:40 ratios were associated with earlier parental onset, while higher Aβ38:40 was associated with a later disease onset. For Aβ42:38 we included a quadratic term (p=0.003), which resulted in the estimated rate of change of Aβ42:38 reducing as parental
AAO increased; a one-year increase in parental AAO was associated with a 9.4% decrease (95% CI: 5.3%, 13.3%; p<0.001) in the geometric mean of Aβ42:38 at age 35 compared a 4.4% decrease (95% CI: 2.9%, 5.9%; p<0.001) in the same measure at age 45. For both Aβ42:40 and Aβ38:40, the association with parental AAO was estimated to be constant across the age range investigated, a one-year increase in parental AAO was associated with a 1.6% decrease (95% CI: 0.2%, 3.1%; p=0.03) in Aβ42:40 and a 1.7% increase (95% CI: 0.4%, 3.0%; p=0.008) in the Aβ38:40. In APP carriers, there were no significant associations between Aβ42:40, Aβ42:38 or Aβ38:40 and parental AAO (all p-values ≥0.18; Supplementary Fig. 2).

In PSEN1 and APP carriers, models that adjusted for sex, parental AAO and ‘normal ageing’ did not find any significant association between either Aβ42:40, Aβ42:38 or Aβ38:40 and EYO (Supplementary Figs. 3,4) (p≥0.06). However, in APP carriers there was weak evidence of an association between Aβ42:40 and EYO: a one-year increase in EYO was associated with a 0.8% decrease (95% CI: 1.6% decrease, 0.0% increase, p=0.06) in the geometric mean of Aβ42:40.

Aβ ratios in plasma and iPSC-conditioned media were highly associated for both Aβ42:40 (rho=0.86, p=0.01) and Aβ38:40 (rho=0.79, p=.02), somewhat less so for Aβ42:38 (rho=0.61, p=0.10) (Fig. 3). While we did not observe perfect agreement in the Aβ42:38 ratio between plasma and iPSC lines (shown by solid line, Fig. 3), the direction of change in this ratio, i.e. either increased or decreased when compared to controls, was largely consistent across media.

**DISCUSSION**

In this study we found increases in plasma Aβ42:40 in both APP and PSEN1 carriers compared to non-carriers and marked differences in Aβ ratios between genotypes: Aβ42:38 was higher
in PSEN1 vs. APP, Aβ38:40 was higher in APP vs. PSEN1. Importantly, more aggressive PSEN1 mutations (those with earlier ages of onset) had higher Aβ42:40 and Aβ42:38 ratios – in-vivo evidence of the pathogenicity of these peptide ratios.

These results offer insights into the pathobiology of ADAD and differential effects of APP/PSEN1 genotype. Increased Aβ42:38 in PSEN1 may be attributed to reduced conversion of Aβ42 (substrate) to 38 (product) relative to non-carriers – in contrast APP carriers showed near identical Aβ42:38 ratios compared to non-carriers. Strikingly, increases in Aβ42 relative to shorter Aβ moieties (≤40) were associated with earlier disease onset in PSEN1. Importantly there were no associations between Aβ ratios and EYO in PSEN1 carriers, suggesting these ratios represent molecular drivers of disease as opposed to being markers of disease stage. Our in-vivo results recapitulate cell-based findings of reduced efficiency of γ-secretase processivity in PSEN1 (Szaruga et al., 2015, 2017; Arber et al., 2019); inefficiency attributed to impaired enzyme-substrate stability causing premature release of longer Aβ peptides (Chávez-Gutiérrez et al., 2012).

Parental AAO is an indicator of disease severity, with a younger AAO implying a more deleterious mutation. In PSEN1 Aβ42:38 (a read-out of the efficiency of the fourth γ-secretase cleavage) showed a deceleration in the rate of change as parental AAO increases. This further supports the central pathogenic role of γ-secretase processivity in ADAD, especially in younger onset, aggressive forms of PSEN1.

In APP, production of Aβ38 relative to Aβ40 was increased. This is consistent with a shift in the site of endopeptidase-cleavage causing increased generation of Aβ48; the precursor substrate in the Aβ38 production line. Our study included APP mutations located near the γ-
secretase cleavage site. Previous cell-based work involving mutations around this site also demonstrated increased trafficking along the Aβ48 pathway (Chávez-Gutiérrez et al., 2012; Szaruga et al., 2017; Arber et al., 2019). In contrast, APP duplications or mutations near the beta-secretase site are associated with non-differential increases in Aβ production (Hunter and Brayne, 2018).

Changes in Aβ38:40 were also seen in PSEN1 carriers; levels were reduced compared to both APP carriers and non-carriers. Declines in Aβ38:40 may reflect mutation effects on endopeptidase cleavage and/or γ-secretase processivity; changes in both processes have been described in in-vitro studies of PSEN1 (Fernandez et al., 2014; Arber et al., 2019). Premature release of longer (>Aβ43) peptides may contribute to falls in Aβ38:40; both increasing Aβ length and pathogenic PSEN1 mutations are associated with destabilisation of the enzyme-substrate complex (Szaruga et al., 2017). It will be important for future research to investigate the exact molecular drivers of declines in Aβ38:40 in PSEN1, especially as lower levels were associated with earlier disease onset.

We also saw inter-stage differences in APP processing; Aβ42:40 was higher in symptomatic compared to presymptomatic PSEN1 carriers. The reason for this is unclear and should be treated cautiously given small group sizes and the absence of inter-stage differences in Aβ42:40 amongst APP carriers. However, post-symptomatic increases in plasma Aβ42 have been reported in Down syndrome (Fortea et al., 2020). It is possible that downstream pathogenic consequences of ADAD, such as cerebral amyloid angiopathy, may interact with, and modify, plasma levels. Additionally, as Aβ is produced peripherally in organs, muscle and platelets, systemic factors may contribute to inter-stage differences (Wang et al., 2017).
Our results support the hypothesis that ADAD mutations increase in-vivo production of longer Aβ peptides (Aβ≥42) relative to Aβ40. This is consistent with cell- and blood-based studies in ADAD (Reiman et al., 2012; Szaruga et al., 2015). Additionally, we showed plasma Aβ profiles were recapitulated in iPSC-media with consistent profiles for the same mutation. There is some evidence that Aβ42:40 ratios also increase in the CSF of mutation carriers far from onset, however CSF levels then fall significantly during the two decades before symptom onset; reductions are attributed to “trapping” of longer peptides within cerebral plaques (Potter et al., 2013, Schindler et al., 2019b). In sporadic AD CSF, as well as plasma, Aβ42:40 levels also fall as cerebral amyloid plaques start to accumulate, with ratio levels remaining low thereafter (Palmqvist et al., 2019). In contrast, we show that plasma Aβ42:40 in both APP and PSEN1 carriers was raised and did not fall below non-carriers levels, either before or after symptom onset. Taken together, these findings suggest that plasma Aβ ratios in ADAD are less susceptible to the confounding effects of sequestration.

Study limitations include the small sample size, due to the rarity of ADAD, however we included a reasonably wide array of mutations. Secondly, ages at onset were estimated from parental AAO, while this offers a reasonable estimate there is variability within families and imprecision in determining AAO in a preceding, often deceased, generation (Pavisic et al., 2020). Finally, future studies should measure Aβ moieties longer than Aβ42, and also investigate interactions between central and peripheral Aβ production (we lacked paired CSF).

In conclusion, we demonstrate the impact of pathogenic ADAD mutation on APP processing in-vivo. We show marked inter-mutation difference in Aβ profiles, with relative increases in longer peptides being associated with earlier disease onset. Our findings suggest that plasma Aβ ratios in ADAD may be useful biomarkers of APP processing. This is especially important
as we enter an era of gene silencing therapies, and personalised medicine, where direct read-outs of gene function will be particularly valuable.

**Contributors:** AOC, NCF, HZ developed the study concept. AOC, PSJW, NSR, and HR contributed to recruitment. Data were collected by AOC, PSJW, HR, CA, NW and NSR. Blood samples were processed by AJH, EA, and IS. The immunoprecipitation mass spectrometry method was developed by JP, KB, HZ, and EP. JP analysed the plasma samples. TP, CF, and JMN carried out the statistical analysis. SM and JMP contributed to the genetic analysis. TP and CF created the figures. AOC, JP, TP, CF, NSR, CA, SW, LCG, KB, HZ, and NCF interpreted the data. AOC and NCF drafted the initial manuscript. All authors reviewed and edited the manuscript and critically revised it for intellectual content.

**Conflicts of interest**

KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. NCF reports consultancy for Roche, Biogen and Ionis, and serving on a Data Safety Monitoring Board for Biogen. HR has undertaken consultancy for Roche.

**Role of the Funder/Sponsor:** The funders and sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Acknowledgements**

AOC is supported by an Alzheimer’s Society clinical research training fellowship (AS-CTF-18-001). CA is supported by a fellowship from the Alzheimer’s Society (AS-JF-18-008) and SW is supported by an Alzheimer’s Research UK Senior Research Fellowship (ARUK-SRF2016B-2). IS is supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. PSJW is supported by an MRC Clinical Research Training Fellowship. NSR is supported by a University of London Chadburn Academic Clinical Lectureship. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). CF, JMN and TP’s academic collaboration with the Dementia Research Centre, UCL is supported by a grant to the DRC.
References


Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto